AMG 609 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Fatty Liver Disease
Conditions
Non-alcoholic Fatty Liver Disease
Trial Timeline
May 24, 2021 → Jul 19, 2023
NCT ID
NCT04857606About AMG 609 + Placebo
AMG 609 + Placebo is a phase 1 stage product being developed by Amgen for Non-alcoholic Fatty Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04857606. Target conditions include Non-alcoholic Fatty Liver Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04857606 | Phase 1 | Completed |
Competing Products
20 competing products in Non-alcoholic Fatty Liver Disease